Best Options By Irritable Bowel Syndrome

Best options by irritable bowel syndrome

1. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome: an evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(suppl 1):S1–35. [PubMed] [Google Scholar]

2. Aguas M, Garrigues V, Bastida G, et al. Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD) J Crohns Colitis.

2011;5(3):227–233. [PubMed] [Google Scholar]

3. Choung RS, Locke R. Epidemiology of IBS.

IBS Blog Posts

Gastroenterol Clin N Am. 2011;40:1–10. [PubMed] [Google Scholar]

4.

Best options by irritable bowel syndrome

Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1474–1482. [PubMed] [Google Scholar]

5.

Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis. 2009;41(12):854–862.[PMC free article] [PubMed] [Google Scholar]

6.

Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491.

Best options by irritable bowel syndrome

[PubMed] [Google Scholar]

7. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770–1798.[PMC free article] [PubMed] [Google Scholar]

8. O’Connor OJ, McSweeney SE, McWilliams S, et al. Role of radiologic imaging in irritable bowel syndrome: evidence-based review. Radiology. 2012;262(2):485–494.

[PubMed] [Google Scholar]

9. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8) doi: 10.1002/14651858.CD003460.pub3.. Article number: CD003460. [PubMed] [CrossRef] [Google Scholar]

10. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogel/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.

Am J Gastroenterol. 2013;108(9):1508–1515. [PubMed] [Google Scholar]

11. Butel MJ. Probiotics, gut microbiota and health. Med Mal Infect. 2014;44(1):1–8. [PubMed] [Google Scholar]

12.

Hoveyda N, Heneghan C, Mahtani K, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology.

INTRODUCTION

2009;9:15.[PMC free article] [PubMed] [Google Scholar]

13. Ford AC, Quigley EMM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014 Jun 17; [Epub ahead of print]. [PubMed] [Google Scholar]

14. Zelnorm [package insert] East Hanover, New Jersey: Novartis; Jul, 2006. [Google Scholar]

15. Thompsan CA. Novartis suspends tegaserod sales at FDA’s request.

Am J Health-Syst Pharm.

Best options by irritable bowel syndrome

2007;64:1020. [PubMed] [Google Scholar]

16.

How to know if you have irritable bowel syndrome (IBS)

Lotronex [package insert] San Diego, California: Prometheus Laboratories, Inc.; Sep, 2010. [Google Scholar]

17. Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

Am J Gastroenterol.

GET FREE EMAIL UPDATES!

2007;102(8):1709–1719. [PubMed] [Google Scholar]

18. Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhea-predominant IBS. Aliment Pharmacol Ther. 2012;36(5):437–448.[PMC free article] [PubMed] [Google Scholar]

19. Amitiza [package insert] Deerfield, Illinois: Takeda; Nov, 2012.

[Google Scholar]

20.

Bitcoin trader einzahlung funktioniert nicht

Drossman DA, Chey WD, Johanson JF, et al. Lupiprostone in patients with constipation-associated irritable bowel syndrome— results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329–341. [PubMed] [Google Scholar]

21.

Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587–599. [PubMed] [Google Scholar]

22.

Irritable Bowel Syndrome: Current and Emerging Treatment Options

Linzess [package insert] Cambridge, Massachusetts: Ironwood Pharmaceuticals, Inc.; Aug, 2012. [Google Scholar]

23. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.

Am J Gastroenterol. 2012;107(11):1714–1724.[PMC free article] [PubMed] [Google Scholar]

24. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Am J Gastroenterol. 2012;107(11):1702–1712. [PubMed] [Google Scholar]

25.

Treatment for Irritable Bowel Syndrome

Food and Drug Administration Center for Drug Evaluation and Research Guidance for industry: irritable bowel syndrome – clinical evaluation of drugs for treatment. May, 2012. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance-Regulatory1.Information/Guidances/UCM205269.pdf. Accessed September 24, 2013.

26. Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral K-opioid agonist, in females with irritable bowel syndrome.

Clin Gastroenterol Hepatol. 2007;5(11):1268–1275.[PMC free article] [PubMed] [Google Scholar]

27. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.

Aliment Pharmacol Ther. 2008;28(2):239–249. [PubMed] [Google Scholar]

28. Tioga Pharmaceuticals Study of asimadoline to treat diarrhea-predominant irritable bowel syndrome (D-IBS) Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/study/NCT01100684?term=asimadoline&rank=4.

Accessed November 19, 2013.

Best options by irritable bowel syndrome

[PMC free article] [PubMed] [Google Scholar]

29. Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Diagnosis & Treatment

Gastroenterology. 2013;145(2):329–338. [PubMed] [Google Scholar]

30. Covington P, Andre D, Davenport M, et al. Eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome: results of 2 randomized, double-blind, placebo-controlled phase III clinical trials of efficacy and safety.

Robinhoods bitcoin trading app

Presented as part of Digestive Disease Week; May 3–6, 2014; Chicago, Illinois. Available at http://files.shareholder.com/downloads/ABEA-4H9PM3/3238878290x0x752274/f0470ebb-e052-4c0c-ad29-23093ccbc694/View%20presentation. Accessed July 11, 2014. [Google Scholar]

31. Xifaxan [package insert] Raleigh, North Carolina: Salix Pharmaceuticals Inc.; Nov, 2010. [Google Scholar]

32. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

Am J Gastroenterol. 2012;107(1):28–35. [PubMed] [Google Scholar]

33. Pimentel M, Lembo A, Chey WD.

Horas magicas en forex

Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. [PubMed] [Google Scholar]

34.

Salix Pharmaceuticals Salix receives anticipated FDA complete response letter on Xifaxan 550-mg tablets non-C IBS supplemental new drug application. Mar 8, 2011.

Best options by irritable bowel syndrome

Available at: http://www.salix.com/news-media/news/index/salix-receives-anticipated-fda-complete-response-letter-on-xifaxan%C2%AE-550-mg-tablets-nonc-ibs-supplemental-new-drug-application.aspx. Accessed January 22, 2014.

35. Salix Pharmaceuticals Irritable bowel syndrome with diarrhea (IBS-D) rifaximin re-treatment study (TARGET3) Clinicaltrials gov; National Library of Medicine.

NLM identifier: NCT01543178. Available at: http://clinicaltrials.gov/ct2/show/NCT01543178?term=rifaximin&rank=19. Accessed January 22, 2014.